EphB6 Protein, Human (HEK293)
EphB6, a kinase-defective receptor, interacts with ephrin-B1 and ephrin-B2, regulating cell adhesion and migration. It inhibits JNK activation, reduces IL-2 secretion and CD25 expression in response to ephrin-B2. EphB6 interacts with CBL, EPHB1, and FYN, highlighting its multifaceted role in cellular signaling. EphB6 Protein, Human (HEK293) is the recombinant human-derived EphB6 protein, expressed by HEK293 , with tag free.
- Species: Human
- Source: HEK293
Biological Activity
EphB6, a kinase-defective receptor, interacts with ephrin-B1 and ephrin-B2, regulating cell adhesion and migration. It inhibits JNK activation, reduces IL-2 secretion and CD25 expression in response to ephrin-B2. EphB6 interacts with CBL, EPHB1, and FYN, highlighting its multifaceted role in cellular signaling. EphB6 Protein, Human (HEK293) is the recombinant human-derived EphB6 protein, expressed by HEK293 , with tag free.
EphB6, a kinase-defective receptor specializing in interactions with members of the ephrin-B family, serves as a binding partner for both ephrin-B1 and ephrin-B2. This receptor intricately regulates cell adhesion and migration, demonstrating a nuanced impact with both positive and negative effects upon stimulation by ephrin-B2. Particularly, EphB6 displays the ability to inhibit JNK activation and attenuate T-cell receptor-induced IL-2 secretion and CD25 expression when prompted by ephrin-B2. Noteworthy interactions include associations with CBL and EPHB1, as well as a ligand-independent interaction with FYN, unveiling the multifaceted nature of EphB6 in cellular signaling pathways.
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag Tag Free
-
Accession
O15197-1 (L32-S594)
-
Molecular Construction
-
N-term
-
EphB6 (L32-S594)
Accession # O15197-1 -
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
EPHB6; Ephrin Type-B Receptor 6; EPH Receptor B6; Human Kinase-Defective Eph-Family Receptor Protein; HEP; EphB6; Tyrosine-Protein Kinase-Defective Receptor EPH-6
-
AA Sequence
LEEVLLDTTGETSEIGWLTYPPGGWDEVSVLDDQRRLTRTFEACHVAGAPPGTGQDNWLQTHFVERRGAQRAHIRLHFSVRACSSLGVSGGTCRETFTLYYRQAEEPDSPDSVSSWHLKRWTKVDTIAADESFPSSSSSSSSSSSAAWAVGPHGAGQRAGLQLNVKERSFGPLTQRGFYVAFQDTGACLALVAVRLFSYTCPAVLRSFASFPETQASGAGGASLVAAVGTCVAHAEPEEDGVGGQAGGSPPRLHCNGEGKWMVAVGGCRCQPGYQPARGDKACQACPRGLYKSSAGNAPCSPCPARSHAPNPAAPVCPCLEGFYRASSDPPEAPCTGPPSAPQELWFEVQGSALMLHWRLPRELGGRGDLLFNVVCKECEGRQEPASGGGGTCHRCRDEVHFDPRQRGLTESRVLVGGLRAHVPYILEVQAVNGVSELSPDPPQAAAINVSTSHEVPSAVPVVHQVSRASNSITVSWPQPDQTNGNILDYQLRYYDQAEDESHSFTLTSETNTATVTQLSPGHIYGFQVRARTAAGHGPYGGKVYFQTLPQGELSSQLPERLS
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)